miRNA in Prostate Cancer: New Prospects for Old Challenges.
Prostate cancer (PCa) is one of the most commonly diagnosed cancers among men but has limited prognostic biomarkers available for follow up. MicroRNAs (miRNAs) are small non-coding RNAs that regulate expression of their target genes. Accumulating experimental evidence reports differential miRNA expression in PCa, and that miRNAs are actively involved in the pathogenesis and progression of PCa. miRNA and androgen receptor signaling cross-talk is an established factor in PCa pathogenesis. Differential miRNA expression was found between patients with high versus low Gleason scores, and was also observed in patients with biochemical failure, hormone-resistant cancer and in metastasis. Metastasis requires epithelial-mesenchymal transition which shares many cancer stem cell biological characteristics and both are associated with miRNA dysregulation. In the era of personalized medicine, there is a broad spectrum of potential clinical applications of miRNAs. These applications can significantly improve PCa management including their use as diagnostic and/or prognostic markers, or as predictive markers for treatment efficiency. Preliminary evidence demonstrates that miRNAs can also be used for risk stratification. Circulatory miRNAs can serve as non-invasive biomarkers in urine and/or serum of PCa patients. More recently, analysis of miRNAs and circulating tumor cells are gaining significant attention. Moreover, miRNAs represent an attractive new class of therapeutic targets for PCa. Here, we summarize the current knowledge and the future prospects of miRNAs in PCa, their advantages, and potential challenges as tissue and circulating biomarkers. Prostate cancer (PCa) is the most commonly diagnosed cancer among men in western populations. The American Cancer Society estimated 239, 590 new cases and 29, 720 expected deaths in the USA in 2013. One in every six men are at risk of developing PCa during their lifetime (1). Currently, the standard biomarker for PCa diagnosis is prostate-specific antigen (PSA), which has its limitations, leading to the risks of PCa over diagnosis and harmful overtreatment. The prognostic value of PSA is also questionable (2). Stepping into the new epoch of personalized medicine, molecular markers are urgently needed to improve the different aspects of PCa management (3). miRNAs represent an attractive class of emerging biomarkers that can help in this regard (4;5).
Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Canada; Department of Laboratory Medicine, and the Keenan Research Centre for Biomedical Science at the Li KaShing Knowledge Institute, St. Michael's Hospital, Toronto, Canada.
Samy M
SM
Mekhail
American International College of Arts and Sciences , Antigua.
Peter G
PG
Yousef
American International College of Arts and Sciences , Antigua.
Stephen W
SW
Jackinsky
Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Canada; Department of Laboratory Medicine, St. Joseph's Health Centre, Toronto, Canada.
Maria
M
Pasic
Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Canada; Department of Laboratory Medicine, and the Keenan Research Centre for Biomedical Science at the Li KaShing Knowledge Institute, St. Michael's Hospital, Toronto, Canada.
George M
GM
Yousef
SNPs; cancer stem cells; circulating tumor cells; miRNA; personalized medicine; prognosis; prostate cancer; tumor markers
PLoS One. 2013 Apr 03;8(4):e59688
23593148
Nat Med. 2004 Jan;10(1):33-9
14702632
Crit Rev Oncol Hematol. 2013 Nov;88(2):338-56
23830807
Nat Rev Clin Oncol. 2011 Feb;8(2):75-84
21045789
Expert Rev Mol Diagn. 2011 Apr;11(3):259-75
21463236
Int J Cancer. 2012 Feb 1;130(3):611-21
21400514
Int J Cancer. 2012 Aug 1;131(3):652-61
22052531
Oncogene. 2008 Mar 13;27(12):1788-93
17891175
Cancer Res. 2013 Feb 1;73(3):1232-44
23233736
Am J Kidney Dis. 2013 May;61(5):798-808
23219107
Int J Mol Sci. 2013 Jul 16;14(7):14785-99
23863690
Epigenetics. 2012 Aug;7(8):940-9
22805767
Prostate. 2011 Feb 15;71(3):326-31
20842666
Nat Rev Urol. 2012 May 22;9(7):397-407
22613932
Prostate. 2012 Sep 15;72(13):1469-77
22298119
Proc Natl Acad Sci U S A. 2012 Sep 18;109(38):15312-7
22949650
Nature. 2013 May 16;497(7449):383-7
23636329
Clin Genitourin Cancer. 2011 Sep;9(1):39-45
21723797
Br J Cancer. 2013 Aug 6;109(3):641-50
23846169
Methods Mol Biol. 2013;936:357-69
23007521
Proc Natl Acad Sci U S A. 2006 Feb 14;103(7):2257-61
16461460
Mol Cancer Res. 2010 Sep;8(9):1175-87
20693306
Int J Cancer. 2013 Aug 1;133(3):544-55
23354685
Nature. 2005 Jun 9;435(7043):834-8
15944708
Ann Intern Med. 2012 Jul 17;157(2):120-34
22801674
Clin Chem. 2013 Nov;59(11):1595-603
23958847
Nat Rev Urol. 2010 May;7(5):286-97
20368743
Oncogene. 2012 Oct 11;31(41):4460-71
22266859
Oncogene. 2014 Jan 9;33(2):135-47
23455326
Int J Mol Sci. 2013 Apr 10;14(4):7757-70
23574937
Urol Oncol. 2013 Aug;31(6):796-801
21880514
Nat Rev Clin Oncol. 2011 Jun 07;8(8):467-77
21647195
Oncol Rep. 2012 Nov;28(5):1831-7
22948942
Mol Cancer Ther. 2012 May;11(5):1166-73
22402125
Prostate Cancer. 2013;2013:539680
23577261
Cancer Res. 2011 Mar 1;71(5):1956-67
21343391
Cancer Res. 2012 Jul 1;72(13):3393-404
22719071
Oncogene. 2011 Oct 13;30(41):4231-42
21532615
PLoS One. 2012;7(10):e47454
23077621
Mol Biol Rep. 2012 Apr;39(4):4571-9
21947843
Oncogene. 2013 Aug 29;32(35):4130-8
23069658
Biol Chem. 2012 Apr;393(5):319-30
22505515
J Cell Mol Med. 2013 Jan;17 (1):30-54
23301832
Int J Cancer. 2011 Feb 1;128(3):608-16
20473869
Clin Chem. 2011 Jul;57(7):954-68
21632885
J Biol Chem. 2013 Jan 4;288(1):1-9
23188821
CA Cancer J Clin. 2013 Jan;63(1):11-30
23335087
Urol Oncol. 2014 Jan;32(1):41.e1-9
24035473
Int J Cancer. 2010 Jul 15;127(2):394-403
19585579
Int J Cancer. 2010 Mar 1;126(5):1166-76
19676045
Cancer Res. 2007 Jul 1;67(13):6130-5
17616669
Expert Opin Biol Ther. 2011 Feb;11(2):145-55
21219233
J Clin Pathol. 2009 Sep;62(9):771-6
19734473
PLoS One. 2013;8(3):e58929
23554959
Curr Pharm Des. 2008;14(21):2040-50
18691114
Clin Chem. 2013 Jan;59(1):158-67
23284016
Cancer Res. 2008 Aug 1;68(15):6162-70
18676839
J Urol. 2011 Jul;186(1):9-11
21571339
Cancers (Basel). 2013 Dec 04;5(4):1676-90
24305656
Carcinogenesis. 2012 Nov;33(11):2018-25
22902544
PLoS One. 2010 Aug 27;5(8):e12445
20805998
Clin Cancer Res. 2011 Feb 15;17(4):928-36
21149617
Nat Cell Biol. 2009 Mar;11(3):228-34
19255566
Pharmacol Ther. 2013 Jan;137(1):55-63
22964086
Cell. 2009 Jan 23;136(2):215-33
19167326
PLoS One. 2013;8(4):e60083
23573233
Cancer Gene Ther. 2009 Mar;16(3):206-16
18949015
Cancer Res. 2011 Jan 15;71(2):550-60
21098088
J Cancer. 2013 May 09;4(5):350-7
23781281
Proc Natl Acad Sci U S A. 2008 Jul 29;105(30):10513-8
18663219
Int J Oncol. 2011 Nov;39(5):1183-92
21769427
Mol Biol Rep. 2012 Jan;39(1):369-73
21556765
Urol Oncol. 2012 May-Jun;30(3):314-8
20843707
Mol Biol Rep. 2011 Mar;38(3):1609-15
20842445